CD123-directed cytotoxins are used to treat blastic plasmacytoid dendritic cell neoplasms (BPDCN), a rare blood malignancy. These medications work by targeting the CD123 protein on cancer cells, delivering a toxin that kills these cells. An example of this type of medication is Elzonris (tagraxofusp), which is usually administered by a healthcare professional as an infusion.